14 October 2020
Russia can vaccinate about 70% of its population against COVID-19, a disease caused by the novel coronavirus, in 10-12 months, head of the N. F. Gamaleya Federal Research Center for Epidemiology and Microbiology Alexander Ginzburg stated.
“We can hope that by late November – early December, millions of doses of the vaccine will be entering civilian circulation every month. In about 10-12 months, we will be able to vaccinate a part of our population, 70%, to create a certain protected layer, so that we can consider the infection vaccine-controlled,” he said during the international research conference “Pandemic 2020: Challenges, Solutions, Consequences” held at the Russian Presidential Academy of National Economy and Public Administration (RANEPA).
On August 11, the Sputnik V vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and became the world’s first registered vaccine against COVID-19 based on the human adenoviral vectors platform. Detailed information on the Sputnik V vaccine, the technological platform of human adenoviral vectors, and other details are available at sputnikvaccine.com
On September 4, a research paper on the results of Phase I and Phase II clinical trials of the Sputnik V vaccine was published in The Lancet, one of the leading international medical journals. Post-registration clinical trials of the Sputnik V vaccine involving 40,000 volunteers are currently ongoing. More than 60,000 volunteers have applied to take part in post-registration trials. The first results of these trials are expected to be published in October-November 2020.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024